Results 21 to 30 of about 18,158,432 (307)

Evaluation of EPISEQ SARS-CoV-2 and a Fully Integrated Application to Identify SARS-CoV-2 Variants from Several Next-Generation Sequencing Approaches [PDF]

open access: yes, 2022
Whole-genome sequencing has become an essential tool for real-time genomic surveillance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) worldwide.
Ligeon, Véronique   +31 more
core   +1 more source

SARS-COV-2.pptx [PDF]

open access: yes, 2020
Presentation given at Melbourne Integrative Genomics on 4/3/2020Abstract:Analysis of Sars-COV-2 direct RNA sequence dataAbstract SARS-Cov-2 (virus leading to COVID-19) transferred from an unknown animal host into humans in November 2019, and has since ...
Lachlan Coin (8249877)
core   +1 more source

geneticin-sars-cov-2 [PDF]

open access: yes, 2022
   Data for Geneticin shows selective antiviral activity against SARS-CoV-2 by interfering with programmed -1 ribosomal ...
Valeria Cagno (13118547)   +1 more
core   +1 more source

Neutralization titers of SARS-CoV-2-nLuc and SARS-CoV-2 variants of concern with sera of macaques prime-boost vaccinated with rVSV-msp-SARS-CoV-2-Gtc. [PDF]

open access: yes, 2021
Three macaques were prime-immunized intramuscularly with 109 PFU rVSVInd-SARS-CoV-2-msp-SF-Gtc and boost-immunized with 109 PFU of rVSVInd-SARS-CoV-2-msp-SF-Gtc 20 days after the prime-immunization.
Taewoo Kim (1456888)   +30 more
core   +1 more source

SARS-CoV-2 Virology

open access: yesInfectious Disease Clinics of North America, 2022
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in 2020 and has led to an unprecedented global pandemic. Understanding the virology behind SARS-CoV-2 infection has provided key insights into our efforts to develop antiviral agents and control the COVID-19 pandemic.
Li, Yijia, Li, Jonathan Z.
openaire   +3 more sources

Interaction of Human ACE2 to Membrane-Bound SARS-CoV-1 and SARS-CoV-2 S Glycoproteins [PDF]

open access: yes, 2020
Severe acute respiratory syndrome virus 2 (SARS-CoV-2) is responsible for the current global coronavirus disease 2019 (COVID-19) pandemic, infecting millions of people and causing hundreds of thousands of deaths.
Romain Gasser   +7 more
core   +1 more source

SARS-CoV-2 introductions and early dynamics of the epidemic in Portugal [PDF]

open access: yes, 2022
© The Author(s) 2022.BACKGROUND: Genomic surveillance of SARS-CoV-2 in Portugal was rapidly implemented by the National Institute of Health in the early stages of the COVID-19 epidemic, in collaboration with more than 50 laboratories distributed ...
Portuguese network for SARS-CoV-2 genomics (Consortium)
core   +1 more source

Profile of SARS-CoV-2 [PDF]

open access: yesWiener klinische Wochenschrift, 2020
SummaryThe recent emergence of a new coronavirus (severe acute respiratory syndrome coronavirus‑2, SARS-CoV-2) that is transmitted efficiently among humans and can result in serious disease and/or death has become a global threat to public health and economy.
Heinz, Franz X., Stiasny, Karin
openaire   +2 more sources

Reporte nº17 – Provincia de Córdoba – 19 de marzo de 2021. Consorcio interinstitucional para la Secuenciación del genoma y estudios genómicos de SARS-COV-2 (Proyecto PAIS) [PDF]

open access: yes, 2021
Fil: Consorcio Argentino de Genómica de SARS-CoV-2; Argentina.Fil: Universidad Nacional de Córdoba. Facultad de Ciencias Médicas. Instituto de Virología Dr. José María Vanella; Argentina.Fil: Gobierno de la Provincia de Córdoba.
Gobierno de la Provincia de Córdoba. Ministerio de Salud. Laboratorio Central   +2 more
core  

Superantigens and SARS-CoV-2

open access: yesPathogens, 2022
It has been posited SARS-CoV-2 contains at least one unique superantigen-like motif not found in any other SARS or endemic coronaviruses. Superantigens are potent antigens that can send the immune system into overdrive. SARS-CoV-2 causes many of the biological and clinical consequences of a superantigen, and, in the context of reinfection and waning ...
Adam Hamdy, Anthony Leonardi
openaire   +3 more sources

Home - About - Disclaimer - Privacy